CN110582512B - 针对il-17a和il-17f二者的单克隆抗体及其用途 - Google Patents

针对il-17a和il-17f二者的单克隆抗体及其用途 Download PDF

Info

Publication number
CN110582512B
CN110582512B CN201780087699.1A CN201780087699A CN110582512B CN 110582512 B CN110582512 B CN 110582512B CN 201780087699 A CN201780087699 A CN 201780087699A CN 110582512 B CN110582512 B CN 110582512B
Authority
CN
China
Prior art keywords
antibody
seq
represented
subject
il17a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780087699.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110582512A (zh
Inventor
董晨
郭丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Xinkanghe Biomedical Technology Co ltd
Zhejiang Xinkanghe Biomedical Technology Co ltd
Original Assignee
Beijing Xinkanghe Biomedical Technology Co ltd
Suzhou Xinkanghe Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xinkanghe Biomedical Technology Co ltd, Suzhou Xinkanghe Biomedical Technology Co ltd filed Critical Beijing Xinkanghe Biomedical Technology Co ltd
Publication of CN110582512A publication Critical patent/CN110582512A/zh
Application granted granted Critical
Publication of CN110582512B publication Critical patent/CN110582512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780087699.1A 2017-03-10 2017-03-10 针对il-17a和il-17f二者的单克隆抗体及其用途 Active CN110582512B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/076278 WO2018161340A1 (en) 2017-03-10 2017-03-10 Monoclonal antibody against both il-17a and il-17f and use of the same

Publications (2)

Publication Number Publication Date
CN110582512A CN110582512A (zh) 2019-12-17
CN110582512B true CN110582512B (zh) 2022-08-30

Family

ID=63448085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087699.1A Active CN110582512B (zh) 2017-03-10 2017-03-10 针对il-17a和il-17f二者的单克隆抗体及其用途

Country Status (7)

Country Link
US (1) US10858427B2 (https=)
EP (1) EP3592771A4 (https=)
JP (1) JP6876156B2 (https=)
KR (1) KR102321861B1 (https=)
CN (1) CN110582512B (https=)
AU (1) AU2017402210B2 (https=)
WO (1) WO2018161340A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003329B (zh) * 2019-04-12 2022-09-27 深圳普瑞金生物药业股份有限公司 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
US11827709B2 (en) * 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN119301153A (zh) * 2022-06-29 2025-01-10 上海齐鲁制药研究中心有限公司 结合il-17a和il-17f的抗体分子及其应用
CN116063493B (zh) * 2022-07-22 2023-09-01 贵州省赛尔生物科技有限公司 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN106336459A (zh) * 2015-07-13 2017-01-18 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1963368B3 (en) * 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
EP1996622A2 (en) * 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
JP5116842B2 (ja) 2007-04-27 2013-01-09 ザイモジェネティクス， インコーポレイテッド ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
RU2474588C2 (ru) * 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
ME02734B (me) * 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
WO2014161570A1 (en) * 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN106336459A (zh) * 2015-07-13 2017-01-18 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
一株中和人IL-17免疫活性的单克隆抗体的制备;孙阳等;《免疫学杂志》;20110701(第07期);全文 *

Also Published As

Publication number Publication date
AU2017402210A1 (en) 2019-10-31
KR20190128677A (ko) 2019-11-18
US10858427B2 (en) 2020-12-08
EP3592771A1 (en) 2020-01-15
AU2017402210B2 (en) 2021-08-19
US20200031919A1 (en) 2020-01-30
JP2020511159A (ja) 2020-04-16
JP6876156B2 (ja) 2021-05-26
WO2018161340A1 (en) 2018-09-13
CN110582512A (zh) 2019-12-17
KR102321861B1 (ko) 2021-11-05
EP3592771A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
CN110582512B (zh) 针对il-17a和il-17f二者的单克隆抗体及其用途
WO2021155634A1 (zh) 抗人tslp抗体及其用途
KR20200047606A (ko) Il-6r 항체와 이의 항원 결합 단편 및 의학적 용도
CN116554323B (zh) 人源化抗il21抗体的开发和应用
CN112638940B (zh) 抗-il-25抗体及其用途
CN117866904B (zh) 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
CN117820480A (zh) 纳米抗体串联体、编码基因及应用
CN118063607A (zh) 抗犬il-31抗体及其用途
JP7696291B2 (ja) 抗ｉｌ‐１７ａ抗体及びその適用
CN110483640A (zh) 白介素-6r的人源化单克隆抗体、其编码基因及应用
CN117820475B (zh) 针对il-17a的新型纳米抗体、药物、制备、方法及应用
JP6930778B2 (ja) 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
CN120399065B (zh) 抗il-17a纳米抗体、药物组合物、方法及用途
CN113698484B (zh) 抗il-23r抗体及其用途
CN117820481B (zh) 新型抗体分子及其制药用途
CN117843804B (zh) 单域抗体串联分子及其序列、产品、制备和应用
CN116948031B (zh) 抗il-23r抗体及其用途
CN119708224A (zh) 一种抗il-31抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Room 801, 8th Floor, Building 7, Dongsheng Huigu, No. 1299 Kehai Avenue, Anchang Street, Keqiao District, Shaoxing City, Zhejiang Province, 312081

Patentee after: Zhejiang Xinkanghe Biomedical Technology Co.,Ltd.

Country or region after: China

Patentee after: Beijing xinkanghe Biomedical Technology Co.,Ltd.

Address before: 215123, Suzhou Industrial Park, Suzhou City, Jiangsu Province, China, No. 218 Xinghu Street, A1 North Building, 3rd Floor, H42 215123

Patentee before: Suzhou xinkanghe Biomedical Technology Co.,Ltd.

Country or region before: China

Patentee before: Beijing xinkanghe Biomedical Technology Co.,Ltd.